idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
03/17/2022 07:23

Attgeno announces the collaboration with a world-leading research center for pulmonary hypertension

Holger Mauelshagen Pressestelle
TransMIT Gesellschaft für Technologietransfer mbH

    The collaboration with TransMIT GmbH, the technology transfer agency of Justus-Liebig-University of Giessen (JLU) involves the TransMIT-Project Division for Pulmonary Pharmacotherapy

    Stockholm/Giessen, March 17, 2022 – Attgeno AB today announces a research collaboration targeting to explore Supernitro (PDNO) as a new potential treatment for pulmonary hypertension by investigating specific drug mechanisms in the pathophysiology of the disease. The collaboration with TransMIT GmbH, the technology transfer agency of Justus-Liebig-University of Giessen (JLU) involves the TransMIT-Project Division for Pulmonary Pharmacotherapy, led by Prof. Dr. Ralph Schermuly, located at JLU with its Excellence Cluster Cardio-Pulmonary Institute (CPI), Germany.

    Professor Ralph Schermuly and Professor Ardeschir Ghofrani of the TransMIT-Project Division for Pulmonary Pharmacotherapy located at JLU and CPI commented: “Advancing translational science in the field of pulmonary hypertension is critical to better explore potential new treatments. Supernitro, a novel intravenous nitric oxide-donor, might offer an innovative treatment option for patients with pulmonary hypertension.”

    “I am very happy that Attgeno enters into this research partnership with TransMIT-Project Division for Pulmonary Pharmacotherapy located at JLU and the CPI. This key cooperation will help to elucidate the full potential of Supernitro. Professor Schermuly and Professor Ghofrani have an impressive track record and have been involved in almost every new drug for pulmonary hypertension entering the market during the last 20 years", says Per Agvald, Attgeno's co-founder and CEO.

    For further information, please contact
    Per Agvald (MD, PhD), CEO
    Telephone: +46 706 457 827
    E-mail: per.agvald@attgeno.com

    Christofer Adding (MD, PhD), CMO
    Telephone: +46 707 886 766
    E-mail: christofer.adding@attgeno.com

    About Attgeno
    Attgeno AB is a privately held Swedish biotech company devoted to development and commercialization of innovative and effective nitric oxide-donating drugs. Its leading drug candidate Supernitro (PDNO) is currently in early (phase I/IIa) clinical development. For further information, please visit www.attgeno.com.

    About Supernitro (PDNO)
    Supernitro is administered as an intravenous infusion, which upon entry into the blood, has an ultra-short half-life rapidly releasing its active moiety nitric oxide (NO). As a result, most of its NO is released just through the short passage through the lung blood circulation where it reacts with the blood vessels and causes them to dilate. By the donation of NO in the lungs, Supernitro replaces the decrease in NO production that is a well-known consequence of different diseases leading to increased risk for pulmonary hypertension.

    About pulmonary hypertension
    Pulmonary hypertension is a condition of increased blood pressure in the arteries of the lungs. Symptoms include shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat. Onset is typically gradual and prognosis poor.
    The pathogenesis of pulmonary hypertension involves the narrowing of blood vessels connected to and within the lungs. This makes it harder for the heart to pump blood through the lungs, as it is much harder to make water flow through a narrow pipe as opposed to a wide one. Over time, the affected blood vessels become stiffer and thicker, in a process known as fibrosis. The mechanisms involved in this narrowing process include vasoconstriction, thrombosis, and vascular remodelling.


    Contact for scientific information:

    Prof. Dr. rer. Nat. Ralph Schermuly
    TransMIT-Projektbereich für
    pulmonale Pharmakotherapie
    c/o JLU Giessen
    Abteilung für pulmonale Pharmakotherapie
    Biomedizinisches Forschungszentrum
    Aulweg 130
    35392 Giessen
    Germany
    Telefon: +49 (641) 99-424 20
    E-Mail: schermuly@transmit.de


    Images

    Attgeno announces the collaboration with research center for pulmonary hypertension
    Attgeno announces the collaboration with research center for pulmonary hypertension

    © Niklas Günther/TransMIT GmbH über Canva(.)com

    Attgeno announces the collaboration with research center for pulmonary hypertension
    Attgeno announces the collaboration with research center for pulmonary hypertension

    © Niklas Günther/TransMIT GmbH über Canva(.)com


    Criteria of this press release:
    Business and commerce, Journalists, Scientists and scholars, Students, all interested persons
    Biology, Medicine, Nutrition / healthcare / nursing
    transregional, national
    Cooperation agreements, Transfer of Science or Research
    English


     

    Attgeno announces the collaboration with research center for pulmonary hypertension


    For download

    x

    Attgeno announces the collaboration with research center for pulmonary hypertension


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).